Correction of Lipid Metabolism Disorders in Diabetes Mellitus with Peptide Drugs.

Bulletin of experimental biology and medicine2020PMID: 32246363

View on PubMed DOI: 10.1007/s10517-020-04764-2

Animal StudySemax

Plain Language Summary

Both Semax and the peptide deltalicin were tested in diabetic rats for their ability to correct abnormal blood fat levels. Both peptides improved the lipid profile — lowering total cholesterol, triglycerides, and LDL while raising protective HDL — though deltalicin produced a stronger overall effect. These results suggest peptide-based drugs may offer a useful approach to managing lipid disorders in diabetes.

Abstract

We studied the effect of peptide drugs deltalicin and Semax on lipid metabolism disturbances in diabetes mellitus. Diabetes mellitus was modeled by single injection of streptozotocin (45 mg/kg) and rats with blood glucose ≥12 mmol/liter were selected for the further experiments. Deltalicin in a dose 100 μg/kg and Semax in a dose 200 μg/kg as well as sulodexide corrected lipid metabolism disorders: the content of total cholesterol, triglycerides, LDL, index of atherogenicity decreased and HDL concentration increased. Deltalicin produced more potent effect on lipid metabolism in rats with diabetes mellitus than sulodexide and Semax, which manifested in a significant decrease in total cholesterol and LDL concentration and index of atherogenicity.

Authors

Elagina, A A; Lyashev, Yu D; Lyashev, A Yu; Pronyaeva, T V; Chahine, A R

Keywords

Semaxdeltalicindiabetes mellituslipid metabolism